AI improves Cochlear implant placement

Auditory specialists placing Cochlear implants in hearing-impaired patients may position the devices better with an assist from AI than with conventional methods, according to researchers in Belgium who have published two case studies in Cochlear Implants International.

Neuroscience doctoral candidate Justine Wathour of the Catholic University of Louvain and colleagues selected two adults who were experiencing disappointing results with their manually fitted Cochlear implants (CIs), according to the study abstract.

One patient had undergone 19 fitting sessions over 17 months yet still could not recognize words spoken in open sets.

The other patient had developed good open-set word recognition over a nine-month period of manual adjustments but struggled to understand speech at soft and loud volume levels.

It took clinicians two tries to get AI-proposed placement just right on the first subject. But on the second try, they used an AI approach based on universal, population-based statistics. This time the patient succeeded with open-set word recognition, and in just three months.

The second patient’s word-recognition scores quickly improved with the AI placement proposals, even at the volume extremes that previously were problematic.

Moreover, the AI-suggested modifications in both cases seemed to be atypical, suggesting the placements probably wouldn’t have been tried without the aid of AI.

Wathour et al. concluded the two case studies “illustrate that adults implanted with manual Cochlear implant fitting may experience an improvement in their auditory results with AI-assisted fitting.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.